Clinical pharmacokinetics and pharmacodynamics of ivosidenib in patients with advanced hematologic malignancies with an IDH1 mutation.

MLA

Fan, Bin, et al. “Clinical Pharmacokinetics and Pharmacodynamics of Ivosidenib in Patients with Advanced Hematologic Malignancies with an IDH1 Mutation.” Cancer Chemotherapy and Pharmacology, vol. 85, no. 5, May 2020, pp. 959–68. EBSCOhost, https://doi.org/10.1007/s00280-020-04064-6.

APA

Fan, B., Dai, D., DiNardo, C. D., Stein, E., de Botton, S., Attar, E. C., Liu, H., Liu, G., Lemieux, I., Agresta, S. V., & Yang, H. (2020). Clinical pharmacokinetics and pharmacodynamics of ivosidenib in patients with advanced hematologic malignancies with an IDH1 mutation. Cancer Chemotherapy and Pharmacology, 85(5), 959–968. https://doi.org/10.1007/s00280-020-04064-6

Chicago

Fan, Bin, David Dai, Courtney D DiNardo, Eytan Stein, Stéphane de Botton, Eyal C Attar, Hua Liu, et al. 2020. “Clinical Pharmacokinetics and Pharmacodynamics of Ivosidenib in Patients with Advanced Hematologic Malignancies with an IDH1 Mutation.” Cancer Chemotherapy and Pharmacology 85 (5): 959–68. doi:10.1007/s00280-020-04064-6.